Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Debt (2024 - 2025)

Apellis Pharmaceuticals (APLS) has 2 years of Non-Current Debt data on record, last reported at $361.7 million in Q4 2025.

  • For Q4 2025, Non-Current Debt rose 0.61% year-over-year to $361.7 million; the TTM value through Dec 2025 reached $361.7 million, up 0.61%, while the annual FY2025 figure was $361.7 million, 0.61% up from the prior year.
  • Non-Current Debt reached $361.7 million in Q4 2025 per APLS's latest filing, roughly flat from $361.1 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $364.0 million in Q2 2024 and bottomed at $359.0 million in Q3 2024.